Abstract
Assessment of a biological system by means of global and non-targeted metabolite profiling—metabolomics or metabonomics—provides the investigator with molecular information that is close to the phenotype in question in the sense that metabolites are an ultimate product of gene, mRNA, and protein activity. Over the last few years, there has been a rapidly growing number of metabolomics applications aimed at finding biomarkers which could assist diagnosis, provide therapy guidance, and evaluate response to therapy for particular diseases. Also, within the fields of drug discovery, drug toxicology, and personalized pharmacology, metabolomics is emerging as a powerful tool. This review seeks to update the reader on analytical strategies, biomarker findings, and implications of metabolomics for the clinic. Particular attention is paid to recent biomarkers found related to neurological, cardiovascular, and cancer diseases. Moreover, the impact of metabolomics in the drug discovery and development process is examined.
Similar content being viewed by others
References
Aharoni A, Ric de Vos CH, Verhoeven HA, Maliepaard CA, Kruppa G, Bino R, Goodenowe DB (2002) Nontargeted metabolome analysis by use of Fourier transform ion cyclotron mass spectrometry. OMICS 6:217–234. doi:10.1089/15362310260256882
Akhtar SN, Singh RK, Jadegoud Y, Dhole TN, Ayyagari A, Nagana Gowda GA (2007) In vitro (1) H NMR studies of RD human cell infection with echovirus 11. NMR Biomed 20:422–428. doi:10.1002/nbm.1099
Appelblad P, Jonsson T, Jiang W, Irgum K (2008) Fast hydrophilic interaction liquid chromatographic separations on bonded zwitterionic stationary phase. J Sep Sci 31:1529–1536. doi:10.1002/jssc.200800080
Barba I, de Leon G, Martin E, Cuevas A, Aguade S, Candell-Riera J, Barrabes JA, Garcia-Dorado D (2008) Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn Reson Med 60:27–32. doi:10.1002/mrm.21632
Beger RD, Schnackenberg LK, Holland RD, Li D, Dragan Y (2006) Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics 2:125–134. doi:10.1007/s11306-006-0026-2
Benecke C, Grund R, Hohberger R, Kerber A, Laue R, Wieland T (1995) Molgen(+), a generator of connectivity isomers and stereoisomers for molecular-structure elucidation. Anal Chim Acta 314:141–147. doi:10.1016/0003-2670(95)00291-7
Benton HP, Wong DM, Trauger SA, Siuzdak G (2008) XCMS2: processing tandem mass spectrometry data for metabolite identification and structural characterization. Anal Chem 80:6382–6389. doi:10.1021/ac800795f
Bertini I, Calabro A, De Carli V, Luchinat C, Nepi S, Porfirio B, Renzi D, Saccenti E, Tenori L (2009) The metabonomic signature of celiac disease. J Proteome Res 8:170–177. doi:10.1021/pr800548z
Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M (2008) Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131:389–396. doi:10.1093/brain/awm304
Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ (2002) Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8:1439–1444. doi:10.1038/nm802
Broeckling CD, Reddy IR, Duran AL, Zhao X, Sumner LW (2006) MET-IDEA: data extraction tool for mass spectrometry-based metabolomics. Anal Chem 78:4334–4341. doi:10.1021/ac0521596
Burns MA, He W, Wu CL, Cheng LL (2004) Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat 3:591–598
Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK, Keun HC (2009) Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 8:352–361. doi:10.1021/pr8006232
Chen C, Krausz KW, Idle JR, Gonzalez FJ (2008a) Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem 283:4543–4559. doi:10.1074/jbc.M706299200
Chen C, Shah YM, Morimura K, Krausz KW, Miyazaki M, Richardson TA, Morgan ET, Ntambi JM, Idle JR, Gonzalez FJ (2008b) Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab 7:135–147. doi:10.1016/j.cmet.2007.12.003
Chen J, Swamidass SJ, Dou Y, Bruand J, Baldi P (2005) ChemDB: a public database of small molecules and related chemoinformatics resources. Bioinformatics 21:4133–4139. doi:10.1093/bioinformatics/bti683
Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL (2005) Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 65:3030–3034
Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073–1077. doi:10.1038/nature04648
Dalgliesh CE, Horning EC, Horning MG, Knox KL, Yarger K (1966) A gas-liquid-chromatographic procedure for separating a wide range of metabolites occurring in urine or tissue extracts. Biochem J 101:792–810
Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Konsgen D, Dietel M, Fiehn O (2006) Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 66:10795–10804. doi:10.1158/0008-5472.CAN-06-0755
Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, Niesporek S, Noske A, Buckendahl A, Dietel M, Fiehn O (2008) Metabolite profiling of human colon carcinoma—deregulation of TCA cycle and amino acid turnover. Mol Cancer 7:72. doi:10.1186/1476-4598-7-72
Erb G, Elbayed K, Piotto M, Raya J, Neuville A, Mohr M, Maitrot D, Kehrli P, Namer IJ (2008) Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magn Reson Med 59:959–965. doi:10.1002/mrm.21486
Fiehn O, Kopka J, Dormann P, Altmann T, Trethewey RN, Willmitzer L (2000) Metabolite profiling for plant functional genomics. Nat Biotechnol 18:1157–1161. doi:10.1038/81137
Fossel ET, Carr JM, McDonagh J (1986) Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 315:1369–1376
Frickenschmidt A, Frohlich H, Bullinger D, Zell A, Laufer S, Gleiter CH, Liebich H, Kammerer B (2008) Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 13:435–449. doi:10.1080/13547500802012858
Gao H, Dong B, Liu X, Xuan H, Huang Y, Lin D (2008) Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal Chim Acta 624:269–277. doi:10.1016/j.aca.2008.06.051
Go EP, Wikoff WR, Shen Z, O'Maille G, Morita H, Conrads TP, Nordstrom A, Trauger SA, Uritboonthai W, Lucas DA, Chan KC, Veenstra TD, Lewicki H, Oldstone MB, Schneemann A, Siuzdak G (2006) Mass spectrometry reveals specific and global molecular transformations during viral infection. J Proteome Res 5:2405–2416. doi:10.1021/pr060215t
Graca G, Duarte IF, Carreira BJG, Couceiro IM, Domingues AB, Mdo R, Spraul M, Tseng LH, Gil AM (2008) Metabolite profiling of human amniotic fluid by hyphenated nuclear magnetic resonance spectroscopy. Anal Chem 80:6085–6092. doi:10.1021/ac800907f
Griffiths WJ, Hornshaw M, Woffendin G, Baker SF, Lockhart A, Heidelberger S, Gustafsson M, Sjovall J, Wang Y (2008) Discovering oxysterols in plasma: a window on the metabolome. J Proteome Res 7:3602–3612. doi:10.1021/pr8001639
Gullberg J, Jonsson P, Nordstrom A, Sjostrom M, Moritz T (2004) Design of experiments: an efficient strategy to identify factors influencing extraction and derivatization of Arabidopsis thaliana samples in metabolomic studies with gas chromatography/mass spectrometry. Anal Biochem 331:283–295. doi:10.1016/j.ab.2004.04.037
Han J, Danell RM, Patel JR, Gumerov DR, Scarlett CO, Speir JP, Parker CE, Rusyn I, Zeisel S, Borchers CH (2008) Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry. Metabolomics 4:128–140. doi:10.1007/s11306-008-0104-8
Hewer R, Vorster J, Steffens FE, Meyer D (2006) Applying biofluid 1H NMR-based metabonomic techniques to distinguish between HIV-1 positive/AIDS patients on antiretroviral treatment and HIV-1 negative individuals. J Pharm Biomed Anal 41:1442–1446. doi:10.1016/j.jpba.2006.03.006
Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, Ebbels T, De Iorio M, Brown IJ, Veselkov KA, Daviglus ML, Kesteloot H, Ueshima H, Zhao L, Nicholson JK, Elliott P (2008) Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453:396–400. doi:10.1038/nature06882
Horning EC, Horning MG (1971) Metabolic profiles: gas-phase methods for analysis of metabolites. Clin Chem 17:802–809
Hosch W, Junghanss T, Stojkovic M, Brunetti E, Heye T, Kauffmann GW, Hull WE (2008) Metabolic viability assessment of cystic echinococcosis using high-field 1H MRS of cyst contents. NMR Biomed 21:734–754. doi:10.1002/nbm.1252
Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, Issaq EJ, Kravstov A, Mullerad M (2008) Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 179:2422–2426. doi:10.1016/j.juro.2008.01.084
Jacobs A (2009) An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs. Toxicol Lett 186(1):32–35
Jonsson P, Johansson AI, Gullberg J, Trygg J, A J, Grung B, Marklund S, Sjostrom M, Antti H, Moritz T (2005) High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. Anal Chem 77:5635–5642. doi:10.1021/ac050601e
Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12:934–945. doi:10.1038/sj.mp.4002000
Kalisiak J, Trauger SA, Kalisiak E, Morita H, Fokin VV, Adams MW, Sharpless KB, Siuzdak G (2009) Identification of a new endogenous metabolite and the characterization of its protein interactions through an immobilization approach. J Am Chem Soc 131:378–386. doi:10.1021/ja808172n
Kamleh A, Barrett MP, Wildridge D, Burchmore RJ, Scheltema RA, Watson DG (2008) Metabolomic profiling using Orbitrap Fourier transform mass spectrometry with hydrophilic interaction chromatography: a method with wide applicability to analysis of biomolecules. Rapid Commun Mass Spectrom 22:1912–1918. doi:10.1002/rcm.3564
Katajamaa M, Oresic M (2005) Processing methods for differential analysis of LC/MS profile data. BMC Bioinformatics 6:179. doi:10.1186/1471-2105-6-179
Katajamaa M, Miettinen J, Oresic M (2006) MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics 22:634–636. doi:10.1093/bioinformatics/btk039
Kawashima H, Oguchi M, Ioi H, Amaha M, Yamanaka G, Kashiwagi Y, Takekuma K, Yamazaki Y, Hoshika A, Watanabe Y (2006) Primary biomarkers in cerebral spinal fluid obtained from patients with influenza-associated encephalopathy analyzed by metabolomics. Int J Neurosci 116:927–936. doi:10.1080/00207450600550519
Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH (2009) Urine metabolomic analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8:558–570
Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Tasan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE (2008) Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118:3503–3512. doi:10.1172/JCI35111
Lin H, Zhang J, Gao P (2009) Silent myocardial ischemia is associated with altered plasma phospholipids. J Clin Lab Anal 23:45–50. doi:10.1002/jcla.20288
Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes E, Nicholson JK (2005) The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6:691–699. doi:10.2217/14622416.6.7.691
Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ (2007) Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One 2:e595. doi:10.1371/journal.pone.0000595
Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfor K, Kristensen GB, Gribbestad IS (2007) Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer 7:11. doi:10.1186/1471-2407-7-11
Ma YL, Qin HL, Liu WJ, Peng JY, Huang L, Zhao XP, Cheng YY (2009) Ultra-high performance liquid chromatography–mass spectrometry for the metabolomic analysis of urine in colorectal cancer. Dig Dis Sci. doi:10.1007/s10620-008-0665-4
Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B (2009) Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed 22(3):342–348
Monleon D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortes O, Gil-Benso R, Lopez-Gines C, Cerda-Nicolas M, Celda B (2008) Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res 7:2882–2888. doi:10.1021/pr800110a
Morvan D, Demidem A (2007) Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res 67:2150–2159. doi:10.1158/0008-5472.CAN-06-2346
Mountford CE, Somorjai RL, Malycha P, Gluch L, Lean C, Russell P, Barraclough B, Gillett D, Himmelreich U, Dolenko B, Nikulin AE, Smith IC (2001) Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br J Surg 88:1234–1240. doi:10.1046/j.0007-1323.2001.01864.x
Munger J, Bennett BD, Parikh A, Feng XJ, McArdle J, Rabitz HA, Shenk T, Rabinowitz JD (2008) Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat Biotechnol 26:1179–1186. doi:10.1038/nbt.1500
Nicholson JK, O'Flynn MP, Sadler PJ, Macleod AF, Juul SM, Sonksen PH (1984) Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. Biochem J 217:365–375
Nicholson JK, Lindon JC, Holmes E (1999) ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29:1181–1189. doi:10.1080/004982599238047
Nicoli F, Vion-Dury J, Confort-Gouny S, Maillet S, Gastaut JL, Cozzone PJ (1996) Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy. C R Acad Sci III 319:623–631
Nordstrom A, O'Maille G, Qin C, Siuzdak G (2006) Nonlinear data alignment for UPLC-MS and HPLC-MS based metabolomics: quantitative analysis of endogenous and exogenous metabolites in human serum. Anal Chem 78:3289–3295. doi:10.1021/ac060245f
Nordstrom A, Want E, Northen T, Lehtio J, Siuzdak G (2008) Multiple ionization mass spectrometry strategy used to reveal the complexity of metabolomics. Anal Chem 80:421–429. doi:10.1021/ac701982e
Northen TR, Yanes O, Northen MT, Marrinucci D, Uritboonthai W, Apon J, Golledge SL, Nordstrom A, Siuzdak G (2007) Clathrate nanostructures for mass spectrometry. Nature 449:1033–1036. doi:10.1038/nature06195
O'Maille G, Go EP, Hoang L, Want EJ, Smith C, O'Maille P, Nordstrom A, Morita H, Qin C, Uritboonthai W, Apon J, Moore R, Garrett J, Siuzdak G (2008) Metabolomics relative quantitation with mass spectrometry using chemical derivatization and isotope labeling. Spectr Int J 22:327–343
Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL (2005) Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 113:782–788. doi:10.1002/ijc.20651
Oliver SG, Winson MK, Kell DB, Baganz F (1998) Systematic functional analysis of the yeast genome. Trends Biotechnol 16:373–378. doi:10.1016/S0167-7799(98)01214-1
Osl M, Dreiseitl S, Pfeifer B, Weinberger K, Klocker H, Bartsch G, Schafer G, Tilg B, Graber A, Baumgartner C (2008) A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics 24:2908–2914. doi:10.1093/bioinformatics/btn506
Pandher R, Ducruix C, Eccles SA, Raynaud FI (2008) Cross-platform Q-TOF validation of global exo-metabolomic analysis: application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002. J Chromatogr B Analyt Technol Biomed Life Sci 877(13):1352–1358
Patterson AD, Li H, Eichler GS, Krausz KW, Weinstein JN, Fornace AJ Jr, Gonzalez FJ, Idle JR (2008) UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 80:665–674. doi:10.1021/ac701807v
Pauling L, Robinson AB, Teranishi R, Cary P (1971) Quantitative analysis of urine vapor and breath by gas–liquid partition chromatography. Proc Natl Acad Sci USA 68:2374–2376. doi:10.1073/pnas.68.10.2374
Pendyala G, Want EJ, Webb W, Siuzdak G, Fox HS (2007) Biomarkers for neuroAIDS: the widening scope of metabolomics. J Neuroimmune Pharmacol 2:72–80. doi:10.1007/s11481-006-9041-3
Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kultz D, Weiss RH (2006) Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 5:64. doi:10.1186/1476-4598-5-64
Phillips M, Gleeson K, Hughes JM, Greenberg J, Cataneo RN, Baker L, McVay WP (1999) Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 353:1930–1933. doi:10.1016/S0140-6736(98)07552-7
Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, Schmitt P (2007) Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomarkers 3:95–109
Plumb R, Castro-Perez J, Granger J, Beattie I, Joncour K, Wright A (2004) Ultra-performance liquid chromatography coupled to quadrupole-orthogonal time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 18:2331–2337. doi:10.1002/rcm.1627
Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M, Mutti A (2005) Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 6:71. doi:10.1186/1465-9921-6-71
Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, Berden JA, Brindle KM, Kell DB, Rowland JJ, Westerhoff HV, van Dam K, Oliver SG (2001) A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol 19:45–50. doi:10.1038/83496
Richardson AD, Yang C, Osterman A, Smith JW (2008) Central carbon metabolism in the progression of mammary carcinoma. Breast Cancer Res Treat 110:297–307. doi:10.1007/s10549-007-9732-3
Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown RH, Kaddurah-Daouk R (2005) Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1:101–108. doi:10.1007/s11306-005-4810-1
Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RE (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112:3868–3875. doi:10.1161/CIRCULATIONAHA.105.569137
Sana TR, Waddell K, Fischer SM (2008) A sample extraction and chromatographic strategy for increasing LC/MS detection coverage of the erythrocyte metabolome. J Chromatogr B Analyt Technol Biomed Life Sci 871:314–321. doi:10.1016/j.jchromb.2008.04.030
Scholz M, Fiehn O (2007) Setup X—a public study design database for metabolomic projects. 13th Pacific Symposium on Biocomputing (PSB), Maui, HI, World Scientific Publ Co Pte Ltd.
Shortreed MR, Lamos SM, Frey BL, Phillips MF, Patel M, Belshaw PJ, Smith LM (2006) Ionizable isotopic labeling reagent for relative quantification of amine metabolites by mass spectrometry. Anal Chem 78:6398–6403. doi:10.1021/ac0607008
Simone IL, Federico F, Trojano M, Tortorella C, Liguori M, Giannini P, Picciola E, Natile G, Livrea P (1996) High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J Neurol Sci 144:182–190. doi:10.1016/S0022-510X(96)00224-9
Slupsky CM, Rankin KN, Wagner J, Fu H, Chang D, Weljie AM, Saude EJ, Lix B, Adamko DJ, Shah S, Greiner R, Sykes BD, Marrie TJ (2007) Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal Chem 79:6995–7004. doi:10.1021/ac0708588
Smith CA, O'Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, Custodio DE, Abagyan R, Siuzdak G (2005) METLIN: a metabolite mass spectral database. Ther Drug Monit 27:747–751. doi:10.1097/01.ftd.0000179845.53213.39
Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G (2006) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78:779–787. doi:10.1021/ac051437y
Stein SE (1999) An integrated method for spectrum extraction and compound identification from gas chromatography/mass spectrometry data. J Am Soc Mass Spectrom 10:770–781. doi:10.1016/S1044-0305(99)00047-1
Tautenhahn R, Bottcher C, Neumann S (2008) Highly sensitive feature detection for high resolution LC/MS. BMC Bioinformatics 9:504. doi:10.1186/1471-2105-9-504
T'Kindt R, Storme M, Deforce D, Van Bocxlaer J (2008) Evaluation of hydrophilic interaction chromatography versus reversed-phase chromatography in a plant metabolomics perspective. J Sep Sci 31:1609–1614. doi:10.1002/jssc.200700539
Tolstikov VV, Fiehn O (2002) Analysis of highly polar compounds of plant origin: combination of hydrophilic interaction chromatography and electrospray ion trap mass spectrometry. Anal Biochem 301:298–307. doi:10.1006/abio.2001.5513
Tzika AA, Astrakas L, Cao H, Mintzopoulos D, Andronesi OC, Mindrinos M, Zhang J, Rahme LG, Blekas KD, Likas AC, Galatsanos NP, Carroll RS, Black PM (2007) Combination of high-resolution magic angle spinning proton magnetic resonance spectroscopy and microscale genomics to type brain tumor biopsies. Int J Mol Med 20:199–208
Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell DB, Barker RA, Grainger DJ, Rubinsztein DC (2006) Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129:877–886. doi:10.1093/brain/awl027
Vaidyanathan S, Gaskell S, Goodacre R (2006) Matrix-suppressed laser desorption/ionisation mass spectrometry and its suitability for metabolome analyses. Rapid Commun Mass Spectrom 20:1192–1198. doi:10.1002/rcm.2434
van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 7:142. doi:10.1186/1471-2164-7-142
van der Werf MJ, Overkamp KM, Muilwijk B, Coulier L, Hankemeier T (2007) Microbial metabolomics: toward a platform with full metabolome coverage. Anal Biochem 370:17–25. doi:10.1016/j.ab.2007.07.022
Walsh MC, Brennan L, Malthouse JP, Roche HM, Gibney MJ (2006) Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. Am J Clin Nutr 84:531–539
Wang JN, Zhou Y, Zhu TY, Wang X, Guo YL (2008) Prediction of acute cellular renal allograft rejection by urinary metabolomics using MALDI-FTMS. J Proteome Res 7:3597–3601. doi:10.1021/pr800092f
Want EJ, O'Maille G, Smith CA, Brandon TR, Uritboonthai W, Qin C, Trauger SA, Siuzdak G (2006a) Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem 78:743–752. doi:10.1021/ac051312t
Want EJ, Smith CA, Qin CA, VanHorne KC, Siuzdak G (2006b) Phospholipid capture combined with non-linear chromatographic correction for improved serum metabolite profiling. Metabolomics 2:145–154. doi:10.1007/s11306-006-0028-0
Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH (2002) Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 43:1809–1817. doi:10.1194/jlr.M200169-JLR200
Werner E, Croixmarie V, Umbdenstock T, Ezan E, Chaminade P, Tabet JC, Junot C (2008) Mass spectrometry-based metabolomics: accelerating the characterization of discriminating signals by combining statistical correlations and ultrahigh resolution. Anal Chem 80:4918–4932. doi:10.1021/ac800094p
Wikoff WR, Gangoiti JA, Barshop BA, Siuzdak G (2007) Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin Chem 53:2169–2176. doi:10.1373/clinchem.2007.089011
Wikoff WR, Pendyala G, Siuzdak G, Fox HS (2008) Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest 118:2661–2669. doi:10.1172/JCI34138
Wiseman JM, Puolitaival SM, Takats Z, Cooks RG, Caprioli RM (2005) Mass spectrometric profiling of intact biological tissue by using desorption electrospray ionization. Angew Chem Int Ed Engl 44:7094–7097. doi:10.1002/anie.200502362
Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, Xiong Y, Clive D, Greiner R, Nazyrova A, Shaykhutdinov R, Li L, Vogel HJ, Forsythe I (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37:D603–D610. doi:10.1093/nar/gkn810
Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, Nam SJ, Kim S, Bai SW, Chung BC (2009) Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 400:63–69. doi:10.1016/j.cca.2008.10.014
Woodcock J, Woosley R (2008) The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1–12. doi:10.1146/annurev.med.59.090506.155819
Xu Y, Du L, Rose MJ, Fu I, Woolf EJ, Musson DG (2005) Concerns in the development of an assay for determination of a highly conjugated adsorption-prone compound in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 818:241–248. doi:10.1016/j.jchromb.2005.01.004
Yan SK, Wei BJ, Lin ZY, Yang Y, Zhou ZT, Zhang WD (2008) A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral Oncol 44:477–483. doi:10.1016/j.oraloncology.2007.06.007
Yang C, Richardson AD, Smith JW, Osterman A (2007) Comparative metabolomics of breast cancer. Pac Symp Biocomput 12:181–192. doi:10.1142/9789812772435_0018
Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S, Yang Q (2004) Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Analyt Technol Biomed Life Sci 813:59–65. doi:10.1016/j.jchromb.2004.09.032
Yu K, Sheng G, Sheng J, Chen Y, Xu W, Liu X, Cao H, Qu H, Cheng Y, Li L (2007) A metabonomic investigation on the biochemical perturbation in liver failure patients caused by hepatitis B virus. J Proteome Res 6:2413–2419. doi:10.1021/pr060591d
Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ (2007) Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol 21:2136–2151. doi:10.1210/me.2007-0150
Acknowledgements
A. N. is supported by The Swedish Research Council (VR) through a junior research position.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nordström, A., Lewensohn, R. Metabolomics: Moving to the Clinic. J Neuroimmune Pharmacol 5, 4–17 (2010). https://doi.org/10.1007/s11481-009-9156-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-009-9156-4